Wang Xuejiao, Yang Guang, Li Jun, Meng Chao, Xue Zengming
Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, No. 5 Beixiange, Xicheng District, Beijing, 100053, China.
Department of Cardiology, Langfang People's Hospital, Hebei Medical University, No. 37, Xinhua Road, Langfang, 065000, China.
Sci Rep. 2024 May 3;14(1):10175. doi: 10.1038/s41598-024-60945-3.
Acute myocardial infarction (AMI) commonly precedes ventricular remodeling, heart failure. Few dynamic molecular signatures have gained widespread acceptance in mainstream clinical testing despite the discovery of many potential candidates. These unmet needs with respect to biomarker and drug discovery of AMI necessitate a prioritization. We enrolled patients with AMI aged between 30 and 70. RNA-seq analysis was performed on the peripheral blood mononuclear cells collected from the patients at three time points: 1 day, 7 days, and 3 months after AMI. PLC/LC-MS analysis was conducted on the peripheral blood plasma collected from these patients at the same three time points. Differential genes and metabolites between groups were screened by bio-informatics methods to understand the dynamic changes of AMI in different periods. We obtained 15 transcriptional and 95 metabolite expression profiles at three time points after AMI through high-throughput sequencing. AMI-1d: enrichment analysis revealed the biological features of 1 day after AMI primarily included acute inflammatory response, elevated glycerophospholipid metabolism, and decreased protein synthesis capacity. Phosphatidylcholine (PC) and phosphatidylethanolamine (PE) might stand promising biomarkers to differentiate post-AMI stage. Anti-inflammatory therapy during the acute phase is an important direction for preventing related pathology. AMI-7d: the biological features of this stage primarily involved the initiation of cardiac fibrosis response and activation of platelet adhesion pathways. Accompanied by upregulated TGF-beta signaling pathway and ECM receptor interaction, GP5 help assess platelet activation, a potential therapeutic target to improve haemostasis. AMI-3m: the biological features of 3 months after AMI primarily showed a vascular regeneration response with VEGF signaling pathway, NOS3 and SHC2 widely activated, which holds promise for providing new therapeutic approaches for AMI. Our analysis highlights transcriptional and metabolomics signatures at different time points after MI, which deepens our understanding of the dynamic biological responses and associated molecular mechanisms that occur during cardiac repair.
急性心肌梗死(AMI)通常先于心室重塑和心力衰竭发生。尽管发现了许多潜在的候选生物标志物,但很少有动态分子特征在主流临床检测中得到广泛认可。这些在AMI生物标志物和药物发现方面未满足的需求需要进行优先排序。我们纳入了年龄在30至70岁之间的AMI患者。在AMI后的3个时间点,即1天、7天和3个月,对从患者采集的外周血单个核细胞进行RNA测序分析。对在相同3个时间点从这些患者采集的外周血血浆进行液相色谱/质谱联用(PLC/LC-MS)分析。通过生物信息学方法筛选组间差异基因和代谢物,以了解AMI在不同时期的动态变化。通过高通量测序,我们在AMI后的3个时间点获得了15个转录组和95个代谢物表达谱。AMI-1d:富集分析显示,AMI后1天的生物学特征主要包括急性炎症反应、甘油磷脂代谢升高和蛋白质合成能力下降。磷脂酰胆碱(PC)和磷脂酰乙醇胺(PE)可能是区分AMI后阶段的有前景的生物标志物。急性期的抗炎治疗是预防相关病理的重要方向。AMI-7d:该阶段的生物学特征主要涉及心脏纤维化反应的启动和血小板黏附途径的激活。伴随着转化生长因子-β信号通路和细胞外基质受体相互作用的上调,GP5有助于评估血小板活化,这是改善止血的潜在治疗靶点。AMI-3m:AMI后3个月的生物学特征主要表现为血管再生反应,血管内皮生长因子(VEGF)信号通路、一氧化氮合酶3(NOS3)和SHC2广泛激活,这有望为AMI提供新的治疗方法。我们的分析突出了心肌梗死后不同时间点的转录组和代谢组特征,加深了我们对心脏修复过程中发生的动态生物学反应和相关分子机制的理解。